Emerging clinical evidence shows that the deregulation of ubiquitin-mediated degradation of
oncogene products or tumour suppressors is likely to be involved in the aetiology of …

A major goal in cancer and aging research is to discriminate the biochemical modifications
that happen locally that could account for the healthiness or malignancy of tissues …

The existence of a small population of 'cancer-initiating cells' responsible for tumour
maintenance has been firmly demonstrated in leukaemia. This concept is currently being …

Abstract Treatment of acute promyelocytic leukemia (APL) with all-trans retinoic acid and/or
arsenic trioxide represents a paradigm in targeted cancer therapy because these drugs …

The p53 tumor suppressor promotes cell cycle arrest or apoptosis in response to stress.
Previous work suggests that the promyelocytic leukemia gene (PML) can act upstream of …

Acute promyelocytic leukemia (APL) is driven by the promyelocytic leukemia (PML)–retinoic
acid receptor-α (PML-RARA) fusion protein, which interferes with nuclear receptor signaling …

Acute promyelocytic leukemia (APL) is a subtype of myeloid leukemia characterized by
differentiation block at the promyelocyte stage. Besides the presence of chromosomal …

PML nuclear bodies (NB) are disrupted in PML-RARA–driven acute promyelocytic leukemia
(APL). Arsenic trioxide (ATO) cures 70% of patients with APL, driving PML-RARA …

Acute promyelocytic leukemia (APL) is driven by a chromosomal translocation whose
product, the PML/retinoic acid (RA) receptor α (RARA) fusion protein, affects both nuclear …

Acute promyelocytic leukemia (APL) is a hematological malignancy driven by the
PML/RARA oncogene. The prognosis for patients with APL was revolutionized by two …